Recruiting
Phase 2

BMS-986511

Sponsor:

Bristol-Myers Squibb

Code:

NCT07772531

Conditions

Major Depressive Disorder

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

BMS-986511

Placebo

Study Details

Brief summary:

A Study to Evaluate BMS-986511 in Adults with Major Depressive Disorder

Conditions

Major Depressive Disorder

Study ID

NCT07772531

Start date

Oct 30, 2026

Status verified date

Nov, 2026

Completion date

Nov 6, 2028

Anticipated

Primary completion date

Nov 6, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participants must meet the MDD diagnosis per DSM-5 criteria confirmed by structured interview.
  • Participant must have current moderate to severe MDE confirmed by clinical assessment and validated scale.
  • Participant must have current MDE duration >12 weeks at screening.
  • Outpatient participants able to comply with study procedures.
  • Participant require medication washout completed before baseline.
  • Participant must have BMI within protocol range.
  • Participants must meet reproductive safety requirements.

Exclusion Criteria:

  • Participants must not have other primary psychiatric disorders or a history of treatment-resistant depression during the current episode.
  • Participants must not have recent history of active suicidal ideation or attempt within the past year.
  • Participants must not have prior lifetime treatment with electroconvulsive therapy, ketamine/esketamine, deep brain stimulation, or transcranial magnetic stimulation.
  • Participants must not have recent history of alcohol/substance abuse or use of cannabis.
  • Participants must not have significant ECG abnormalities, or poorly controlled diabetes.
  • Other protocol defined inclusion/exclusion criteria apply.

Study Design

Enrollment

200 participants

Anticipated

Allocation

Randomized

Intervention Model

Sequential

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: BMS-986511: Dose A

experimental: BMS-986511: Dose B

experimental: Placebo

Interventions

BMS-986511

Specified dose on specified days

Placebo

Specified dose on specified days

Primary outcome measure

  • Mean change from baseline in Hamilton Depression Rating Scale -17 Item (HDRS-17) total score [ Time Frame: Up to Day 57 ]

Central Contacts and Locations

Central contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

855-907-3286Clinical.Trials@bms.com

Locations

Woodland International Research Group

Recruiting

Little Rock, Arkansas, United States, 72211

Contacts

George Konis, Site 0038

501-221-8681

Woodland Research Northwest LLC

Recruiting

Rogers, Arkansas, United States, 72758

Contacts

Ryan Mahelona, Site 0047

479-927-3000

CenExel CBH

Recruiting

Atlanta, Georgia, United States, 30331

Contacts

Elyssa Barron, Site 0140

404-881-5800

More Information

Sponsor

Bristol-Myers Squibb

Last update posted

Nov 18, 2026

Last verified

Nov, 2026

Keywords

  • Major Depressive Disorder
  • Depression
  • BMS-986511
  • Evifacotrep
  • TRPC4/5 Inhibitor
  • Antidepressant
  • Mood Disorders
  • Central Nervous System
  • MDD

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Bristol-Myers Squibb on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.